The serum antibody levels to SH3GL1 mut-1 and mut-3 in the patients with low-grade glioma were still significantly higher than those in other groups (Figures4B and D), while the levels of anti-SH3GL1 mut-2 showed no difference among the groups (Figure4C). This evidence concerns the gene SH3GL1 and glioma.